Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients

被引:19
|
作者
Ramos, Ana M. [1 ]
Albalate, Marta [1 ]
Vazquez, Silvia [2 ]
Caramelo, Carlos [1 ]
Egido, Jesus [1 ]
Ortiz, Alberto [1 ]
机构
[1] Autonomous Univ Madrid, Jimenez Diaz Fdn Capio, Nephrol & Hypertens Unit, E-28049 Madrid, Spain
[2] Autonomous Univ Madrid, Jimenez Diaz Fdn Capio, Stat Unit, E-28049 Madrid, Spain
关键词
chronic kidney disease; bone mineral metabolism; PTH; hyperphosphatemia;
D O I
10.1038/ki.2008.543
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Disturbances in bone and mineral metabolism are common in chronic kidney disease (CKD) patients. Most studies have been performed in hemodialysis and there is less information on non-dialysis patients, on the coexistence of other risk factors and on the achievement of more recent and stringent guidelines. Cross sectional study of analytical mineral and bone parameters in 125 incident patients (creatinine clearance <60 ml/min) in a monographic CKD clinic. Evaluation after one year of follow-up in 69 patients. Progression of CKD was associated with significant increased levels of phosphate, calcium x phosphate and iPTH and decreased calcium and 1,25 dihydroxyvitamin D. Levels of 25-hydroxyvitamin D were unchanged, but lower than recommended. Phosphate correlated negatively with 1,25-dihydroxyvitamin D and creatinine clearance, and positively with iPTH. At every stage of CKD, most patients had PTH values outside recommended limits. More than 69% CKD 3 and CKD 4 patients had higher than recommended PTH levels. Above recommended phosphate levels were present in 25% of CKD 4 and 47% of CKD 5 patients. Most of these had associated high LDL-cholesterol. Higher than recommended calcium levels were more prevalent than low calcium and there was a high prevalence (31%) of vascular calcification. One year of intervention improved the percentage of patients with controlled calcium or iPTH, but not phosphate. In incident CKD patients there is a high prevalence of out-of-target mineral and bone analytical parameters. The currently authorized therapeutic arsenal for these patients may not be adequate to deal with the problem.
引用
收藏
页码:S88 / S93
页数:6
相关论文
共 50 条
  • [2] Comparison of the association intensity of creatinine and cystatin C with hyperphosphatemia and hyperparathyroidism in patients with chronic kidney disease
    Byungju Min
    Sung-Ro Yun
    Se-Hee Yoon
    Jong-Dai Kim
    Wan Jin Hwang
    Won Min Hwang
    Yohan Park
    Scientific Reports, 13
  • [3] Persistent uncertainties in optimal treatment approaches of secondary hyperparathyroidism and hyperphosphatemia in patients with chronic kidney disease
    Cortes, Daniela Del Pilar Via Reque
    Drueke, Tilman B.
    Moyses, Rosa Maria Affonso
    CURRENT OSTEOPOROSIS REPORTS, 2024, : 441 - 457
  • [4] Comparison of the association intensity of creatinine and cystatin C with hyperphosphatemia and hyperparathyroidism in patients with chronic kidney disease
    Min, Byungju
    Yun, Sung-Ro
    Yoon, Se-Hee
    Kim, Jong-Dai
    Hwang, Wan Jin
    Hwang, Won Min
    Park, Yohan
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] Hyperphosphatemia Management in Patients with Chronic Kidney Disease
    Shaman, Ahmed M.
    Kowalski, Stefan R.
    SAUDI PHARMACEUTICAL JOURNAL, 2016, 24 (04) : 494 - 505
  • [6] Synbiotics as a novel therapeutic approach for hyperphosphatemia and hyperparathyroidism in chronic kidney disease rats
    Anegkamol, Weerapat
    Bowonsomsarit, Wirin
    Taweevisit, Mana
    Tumwasorn, Somying
    Thongsricome, Thana
    Kaewwongse, Maroot
    Pitchyangkura, Rath
    Tosukhowong, Piyaratana
    Chuaypen, Natthaya
    Dissayabutra, Thasinas
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [7] Hyperphosphatemia of chronic kidney disease
    Hruska, Keith A.
    Mathew, Suresh
    Lund, Richard
    Qiu, Ping
    Pratt, Raymond
    KIDNEY INTERNATIONAL, 2008, 74 (02) : 148 - 157
  • [8] Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis
    Nolan, CR
    Qunibi, WY
    KIDNEY INTERNATIONAL, 2005, 67 : S13 - S20
  • [9] Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis
    Locatelli, Francesco
    Dimkovic, Nada
    Spasovski, Goce
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2015, 10 (02) : 131 - 142
  • [10] The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
    Shigematsu, Takashi
    Nakashima, Yuri
    Ohya, Masaki
    Tatsuta, Koichi
    Koreeda, Daisuke
    Yoshimoto, Wataru
    Yamanaka, Shintaro
    Sakaguchi, Toshifumi
    Hanba, Yoshiyuki
    Mima, Toru
    Negi, Shigeo
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2012, 5 : 81 - 89